On June 24, 2025, Novo Nordisk, the Danish pharmaceutical company known for its insulin production, launched Wegovy, a highly anticipated weight-loss drug, in India. This once-a-week semaglutide injection is aimed at addressing the growing obesity epidemic in the country, where over 250 million individuals are classified with general obesity and approximately 351 million with abdominal obesity. Currently, around 24% of Indian adults fall into the overweight or obese category, highlighting the critical need for effective weight management solutions.
The Drug Controller General of India (DCGI) approved Wegovy for chronic weight management and to reduce cardiovascular events following a selective trial in February 2025. Wegovy is available in five different dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. The cost of the drug is positioned to attract attention; the starter doses ranging from 0.25 mg to 1 mg will be priced at approximately Rs 4,366 per week (around $50.7), which translates to about Rs 17,345 per month. Meanwhile, the higher doses of 1.7 mg and 2.4 mg will be priced at Rs 24,280 and Rs 26,015 per month, respectively. However, pricing remains a significant concern in India’s price-sensitive market, raising questions about accessibility for the vast population struggling with obesity.
To gain a competitive advantage, Novo Nordisk expedited its launch of Wegovy, originally set for 2026, to mid-2025 to outpace competitors like Eli Lilly’s Mounjaro, which is also gaining traction in the Indian market. The company has ambitious targets, aiming to achieve $1 billion in sales within five to seven years in India, reflecting a strong belief in the potential demand for the product. In preparation for a scaling operation, Novo has invested more than $23 billion in production capacity and plans to operate its facilities around the clock.
In India, Novo is not only focusing on distributing Wegovy but is also actively establishing obesity clinics, training healthcare professionals, and collaborating with state governments to enhance obesity care. As the market develops, Wegovy will face competition from Eli Lilly’s Mounjaro, which has already made inroads into the Indian market. Moreover, with the patent for semaglutide set to expire in 2026 in India, local pharmaceutical companies such as Sun Pharma, Cipla, Dr. Reddy’s, and Biocon are working on developing generic versions of the drug.
The situation is complicated further by a patent infringement lawsuit filed by Novo against Dr. Reddy’s Laboratories and OneSource aimed at preventing them from producing generic semaglutide products. However, a Delhi High Court ruling has temporarily restricted these generic advances pending a hearing scheduled for August. Despite the robust demand for Wegovy, affordability remains a pressing issue, and the company is attempting to balance the need for pricing that aligns with the local market conditions while maintaining a premium positioning for the drug. Wegovy is noted for demonstrating an approximate 15% body weight loss in global clinical trials, alongside its efficacy in reducing major cardiovascular events, thereby distinguishing itself in the competitive obesity treatment landscape.
-Raja Aditya
